nimesulide Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1935 51803-78-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nimesulide
  • mesulide
  • mesulid
  • nimsulid
  • sulidene
  • sulide
  • sulidan
  • Molecular weight: 308.31
  • Formula: C13H12N2O5S
  • CLOGP: 3.21
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 1
  • TPSA: 101.22
  • ALOGS: -4.23
  • ROTB: 4

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.27 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Jan. 1, 1985 YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Renal failure neonatal 84.14 22.33 13 2533 123 46683393
Drug abuse 79.48 22.33 47 2499 63361 46620155
Ductus arteriosus stenosis foetal 63.86 22.33 10 2536 104 46683412
Neonatal respiratory acidosis 62.92 22.33 9 2537 47 46683469
Cyanosis neonatal 44.15 22.33 8 2538 209 46683307
Bradycardia neonatal 41.31 22.33 9 2537 611 46682905
Neonatal respiratory distress syndrome 37.31 22.33 11 2535 2522 46680994
Hypertransaminasaemia 33.85 22.33 11 2535 3477 46680039
Abdominal pain upper 32.89 22.33 40 2506 145265 46538251
Contraindication to medical treatment 30.57 22.33 7 2539 596 46682920
Pancreatic enzymes increased 29.58 22.33 7 2539 688 46682828
Atrioventricular block complete 28.79 22.33 12 2534 7615 46675901
Intentional self-injury 27.84 22.33 17 2529 24149 46659367
Tonsillar exudate 27.63 22.33 4 2542 23 46683493
Diabetic metabolic decompensation 25.87 22.33 7 2539 1178 46682338
Gastritis erosive 25.69 22.33 10 2536 5320 46678196
Angioedema 24.64 22.33 19 2527 39323 46644193
Premature baby 24.14 22.33 14 2532 18098 46665418
Jaundice 22.73 22.33 16 2530 28829 46654687

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Ligament calcification 64.91 34.84 9 1157 54 29951258
Body mass index abnormal 61.90 34.84 9 1157 79 29951233
Palmoplantar pustulosis 46.62 34.84 7 1159 78 29951234
Rash maculovesicular 45.49 34.84 6 1160 23 29951289
Confabulation 43.60 34.84 7 1159 124 29951188
Ankylosing spondylitis 43.14 34.84 13 1153 4521 29946791
Lip erythema 42.99 34.84 6 1160 38 29951274
Sacroiliitis 41.42 34.84 9 1157 851 29950461
Spinal pain 39.05 34.84 12 1154 4452 29946860
Mixed liver injury 38.71 34.84 10 1156 1983 29949329
Nasal mucosal disorder 37.38 34.84 6 1160 106 29951206
Negativism 35.97 34.84 7 1159 383 29950929
Face oedema 34.92 34.84 14 1152 11320 29939992
Genital ulceration 34.92 34.84 6 1160 163 29951149

Pharmacologic Action:

SourceCodeDescription
ATC M01AX17 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Other antiinflammatory and antirheumatic agents, non-steroids
ATC M02AA26 MUSCULO-SKELETAL SYSTEM
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Antiinflammatory preparations, non-steroids for topical use
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drugs
CHEBI has role CHEBI:50629 cyclooxygenase-2 inhibitor

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 6.03 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium-dependent dopamine transporter Transporter Ki 4.93 DRUG MATRIX
Interstitial collagenase Enzyme IC50 4.63 DRUG MATRIX
Prostaglandin G/H synthase 1 Enzyme IC50 5.42 CHEMBL
Myeloperoxidase Enzyme IC50 5.68 CHEMBL
cAMP-specific 3',5'-cyclic phosphodiesterase 4A Enzyme IC50 5.70 WOMBAT-PK
Prostaglandin G/H synthase 2 Enzyme IC50 5.91 WOMBAT-PK
Aromatase Enzyme IC50 4.57 WOMBAT-PK
Prostaglandin G/H synthase 1 Enzyme IC50 5.21 CHEMBL
Prostaglandin G/H synthase 2 Enzyme IC50 6.40 CHEMBL
Sodium-dependent neutral amino acid transporter B(0)AT1 Unclassified INHIBITOR IC50 4.64 IUPHAR

External reference:

IDSource
D01049 KEGG_DRUG
C1436417 UMLSCUI
CHEBI:44445 CHEBI
NIM PDB_CHEM_ID
CHEMBL56367 ChEMBL_ID
DB04743 DRUGBANK_ID
C012655 MESH_SUPPLEMENTAL_RECORD_UI
7401 IUPHAR_LIGAND_ID
4885 INN_ID
V4TKW1454M UNII
4495 PUBCHEM_CID
53694 RXNORM
004182 NDDF
703479000 SNOMEDCT_US
703480002 SNOMEDCT_US

Pharmaceutical products:

None